The occurrence and development of neurological diseases are closely related to the abnormal functions of ion channels, such as Na+ channel, K+ channel, Ca2+ channel, cl-channel and TRP channel. The research and development of ion channel drugs has a high threshold and requires a proprietary equipment platform. In order to speed up the research and development progress and improve the research and development efficiency, lidao has established a complete ion channel drug research and development platform, mainly including manual patch clamp system and fluorescence imaging system. The establishment of the platform to make glass that has the ability to study explore almost all of the ion channels, and validation of the level of cell in vitro activity, as well as the heart and nervous system safety security related ion channels in vitro activity screening, such as hERG, Nav1.5, GABA A, AMPA and NMDA receptors, GlyR and nAChR, provide A solid foundation for project propulsion. In addition to in vitro test, the platform can be used in the detection of neurons in the body, such as the DRG neurons, trigeminal nerve, sympathetic neurons in SCG and hippocampal neurons, through a single ion channel activity and the overall changes in the excitability of neurons, and related ion neurons load situation, comprehensive evaluation of compound direct effects on the nervous system. In addition, some peptides separated from small RNA molecules and biological venom can also be detected on this electrophysiological platform on the condition that the activity is guaranteed. After the completion of the platform, it can help lidao realize the vision of a domestic first-class and internationally leading ion channel drug design and discovery base, promote the transformation of basic research into innovative drugs, and achieve a major breakthrough in the research and development of class 1 new drugs with complete independent intellectual property rights.